Previous 10 | Next 10 |
Introduction It’s closing in on almost 3-years since I first published my initial write-up on Viking Therapeutics ( VKTX ) back in Oct-2017. I’ve had plenty to say about the company since that time, publishing numerous other articles along the way, but more recently I’...
Galmed Pharmaceuticals Ltd. (GLMD) Q2 2020 Results Conference Call August 06, 2020 08:30 AM ET Company Participants Allen Baharaff - President and CEO Dr. Tali Gorfine - CMO Yohai Stenzler - CFO Dr. Liat Hayardeny - CSO Conference Call Participants Steve Seedhouse - Raymo...
Galmed (NASDAQ: GLMD ) : Q2 GAAP EPS of -$0.26 beats by $0.06 . More news on: Galmed Pharmaceuticals Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...
TEL AVIV, Israel , Aug. 6, 2020 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol ™ , an oral therapy for the treatment of nonal...
TEL AVIV, Israel , Aug. 6, 2020 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases provides today updated information on the Company's pipeline program. ...
TEL AVIV, Israel , July 30, 2020 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1 modulator, currently in a Phase 3 clinical trial for the...
Quick Take Inventiva SA ( IVA ) intends to raise $102 million in an IPO of ADSs representing underlying ordinary shares, according to an amended registration statement . The company is developing treatments for NASH (Non Alcoholic Steato Hepatitis), MPS (Mucopolysaccharidosis) and other c...
Quick Take Inventiva S.A. ( IVA ) has filed to raise $90 million in an IPO of its ADSs representing ordinary shares, according to an F-1 registration statement. The firm is a clinical stage biopharma developing treatments for NASH (non alcoholic steato hepatitis), MPS (mucopolysaccharido...
Galmed Pharmaceuticals Ltd. (GLMD) Q1 2020 Earnings Conference Call May 14, 2020, 08:30 AM ET Company Participants Allen Baharaff - Chairman, CEO & President Yohai Stenzler - CFO & Controller Liat Hayardeny - Chief Scientific Officer Tali Gorfine - Chief Medical Officer...
Galmed (NASDAQ: GLMD ): Q1 GAAP EPS of -$0.29 beats by $0.08 . More news on: Galmed Pharmaceuticals Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Galmed Pharmaceuticals Ltd. Company Name:
GLMD Stock Symbol:
NASDAQ Market:
Galmed Pharmaceuticals Ltd. Website: